Reckitt Benckiser moved to the top of the risers after a bullish update from Barclays.
Over the counter sales this quarter should be strong it said, driven by a strong flu season and easy comparison to a year ago.
Nielsen market data suggests high double-digit, or even triple-digit, growth in cold and flu treatment Mucinex.
Added to consumers switching away from rival Abbott, this could potentially add 4% to group organic sales and 6% to EPS this year.
Nielsen data suggests strong growth for the quarter, but this may include an element of retailer destocking and consumer pantry-loading.
Reckitt’s product mix and operational gearing meanwhile should also help offset headwinds from rising oil prices, even with low visibility.
The share price target is 9,100p against 6,032p, up 3.4% today.